Sight Sciences, Inc. (NASDAQ:SGHT)
| Market Cap | 441.21M+127.1% |
| Revenue (ttm) | 83.38M+9.3% |
| Net Income | -29.76M+39.3% |
| EPS | -0.56+41.8% |
| Shares Out | 54.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133,579 |
| Open | 8.32 |
| Previous Close | 8.47 |
| Day's Range | 7.84 - 8.32 |
| 52-Week Range | 3.19 - 9.71 |
| Beta | 2.45 |
| Analysts | Buy |
| Price Target | 7.00(-13.68%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About SGHT
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SGHT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SGHT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SGHT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SGHT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SGHT Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Interventional Glaucoma | $20.71M | 86.07% |
| Interventional Dry Eye | $2.67M | 11.12% |
| Investment income | $678.00K | 2.82% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SGHT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SGHT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SGHT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $9.71M |
| IWMiShares Russell 2000 ETF | $8.89M |
| VXFVanguard Extended Market ETF | $3.47M |
| IWOiShares Russell 2000 Growth ETF | $3.05M |
| VTWOVanguard Russell 2000 ETF | $1.92M |
| SMLFiShares U.S. Small-Cap Equity Factor ETF | $1.87M |
Estimated from each fund’s disclosed top holdings × AUM
SGHT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SGHT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score